Pace Hospitals | Best Hospitals in Hyderabad, Telangana, India
DYSLIPIDEMIA TREATMENT

Best Dyslipidemia​ Treatment​ in Hyderabad, India

PACE Hospitals is recognized as the best hospital for dyslipidemia treatment in Hyderabad, Telangana, India,  offering a holistic approach to managing cholesterol disorders. Our expert team of cardiologists and endocrinologists specializes in treating dyslipidemia by reducing LDL (bad cholesterol), increasing HDL (good cholesterol), and maintaining triglyceride levels to prevent serious cardiovascular complications.


Dyslipidemia, also known as hyperlipidemia or high cholesterol, is a common but serious condition characterized by abnormal cholesterol and lipid levels, significantly increasing the risk of heart disease and stroke. At PACE Hospitals, we provide top-quality dyslipidemia treatment in Hyderabad through Advanced diagnostic testing, personalized treatment plans, Medical therapy with lipid-lowering drugs and Ongoing monitoring and risk assessment. With a patient-centric approach, we help individuals effectively manage and treat high cholesterol (hyperlipidemia) to improve their overall health and well-being.

Call us : 040 4848 6868

Book an appointment for Dyslipidemia Treatment​

Dyslipidemia treatment​ - appointment

  • Quick Navigation


Why Choose PACE Hospitals for Dyslipidemia (High cholesterol or Hyperlipidemia) Treatment?

Best Dyslipidemia Treatment​ Hospital in Hyderabad, India | Treatment for Dyslipidemia in Hyderabad | Best Hospital for Dyslipidemia Treatment​ in Hyderabad India
Best Dyslipidemia Treatment in Hyderabad, India

State-of-the-art Diagnostic Testing Facilities

Dyslipidemia Treatment in Hyderabad with Best cardiologists and endocrinologists

Best Cardiologists and Endocrinologists in Hyderabad, India

Treatment for Dyslipidemia in Hyderabad India

Comprehensive Lipid Profile or Lipoprotein Panel Testing 

Reliable Dyslipidemia Treatment in Hyderabad, India

Medical Therapy & Advanced Cardiac Risk Assessment

Dyslipidemia (High cholesterol or Hyperlipidemia) diagnosis in Hyderabad India

Dyslipidemia diagnosis

Dyslipidemia, which is a crucial risk factor for cardiovascular disease, requires comprehensive diagnostic evaluations for accurate assessment. It often progresses silently, so routine lipid screening remains a cornerstone for early detection and management.

🔷 The approach of the general physician toward the patient

Primarily dyslipidemia does not show any symptoms, only patients with severe, untreated dyslipidemia present signs and symptoms which are related to dyslipidemia complications. Therefore, understanding signs and symptoms is important for intervention and prevention of associated complications. 


The general physician considers the following before selecting the appropriate tests to diagnose dyslipidemia: 


General physicians gather the complete medical history of the patient, including family history, as an initial approach to diagnose dyslipidemia. Clinicians need to consider family history and risk factors to guide appropriate intervention. 


The doctor enquires about the following: 


  • Medical history of the patient
  • Pertinent habitual history (tobacco use, alcohol consumption) 
  • Past medical history of the patient
  • Family history of dyslipidemia (to identify familial hypercholesterolemia)
  • Dietary history
  • Other risk factors such as
  • Obesity
  • Age 
  • Physical inactivity
  • Type II diabetes mellitus
  • Hypothyroidism
  • Chronic kidney disease (CKD)
  • Presence of any comorbidities.

🔷 Dyslipidemia screening

Screening is performed regularly, especially for individuals with a family history or with other risk factors. The frequency and type of screening depend on the patient’s age, sex, and health. There is ongoing debate about the age at which screenings must be performed. 


Following are the dyslipidemia guidelines:


  • The National Cholesterol Education Program provides guidelines recommending a fasting lipid panel every 5 years for adults aged 20 years and above.
  • The US Preventive Services Task Force recommends lipid screening in men aged 35 and older, and in women 45 years and older. Younger adults who have cardiovascular risk factors are advised to get screening. Otherwise, fasting lipid panels are suggested for individuals aged between 20 to 78 for every 5 years if no atherosclerotic disease is present. 
  • Screening for dyslipidemia in children and adolescents of age 9 to 11 years and 17 to 21 is recommended by the American Academy of Pediatrics regardless of risk factors whereas selective screening is suggested for patients aged 2 to 6 years and 12 to 16 years having family history of dyslipidemia or cardiovascular diseases (CVD) or with risk factors like obesity, hypertension, diabetes or smoking. 


  • Apart from screening, the first phase of the dyslipidemia management approach involves cardiovascular risk stratification (increased, moderate, or high-risk cardiovascular development in 10 years). In children, high-risk conditions are uncommon. 

🔷 The other necessary lab tests a general physician may consider in establishing the diagnosis of dyslipidemia

Based on the above information, a general physician advises diagnostic tests to detect dyslipidemia. The following are the tests that might be recommended to diagnose dyslipidemia:


Usually, dyslipidemia does not cause any symptoms, but it can be detected or evaluated by a blood test that measures lipid levels of the body. A fasting lipid panel comprising total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides is the primary evaluation for dyslipidemia. 


Following are the lipid levels


Total Cholesterol 

  • Desirable: less than 200 mg/dl
  • Borderline: 200 mg/dl to 239 mg/dl
  • High: greater than or equal to 240mg/dl


Low Density Lipoprotein Cholesterol 

  • Optimal: less than 100mg/dl
  • Near optimal: 100mg/dL to 129 mg/dL
  • Borderline high: 130mg/dL to 159mg/dL
  • High: 160mg/dL to 189mg/dL
  • Very high: greater than or equal to 190mg/dL


High – Density Lipoprotein Cholesterol

  • Low: Less than 40mg/dL in men and less than 50 mg/dL in women
  • High: Greater than equal to 60 mg/dL


Triglycerides

  • Normal: Less than 150 mg/dL
  • Borderline: 150 mg/dL to 199 mg/dL
  • High: 200 mg/dL to 499 mg/Dl
  • Very high: More than or equal to 500 mg/dL

✅ Dyslipidemia diagnostic tests

Apart from lipid panel tests, other diagnostic tests can be used to diagnose dyslipidemia and to exclude secondary causes of dyslipidemia. These dyslipidemia laboratory tests include urine analysis, plasma creatinine, thyroid stimulating hormone (TSH), alkaline phosphatase, and transaminase.

✅ Stages of dyslipidemia

According to Frederickson, dyslipidemia is classified into five phenotypes, and they are as follows: 

  • Phenotype I: It is a chylomicron abnormality and results in an increase of triglycerides more than 99 percentiles. 
  • Phenotype IIa: It includes abnormality of low-density lipoprotein (LDL) cholesterol, and the concentration of total cholesterol is greater than 90 percentiles.                                                                                                           
  • Phenotype IIb: It includes abnormality of low-density lipoprotein (LDL) and very low-density lipoprotein cholesterol (VLDL). In this type, total cholesterol or triglycerides are greater than 90 percentiles.     
  • Phenotype III: It is an abnormality of very low-density lipoprotein (VLDL) and chylomicrons resulting in elevated total cholesterol.
  • Phenotype IV: It is an abnormality of very low-density lipoprotein (VLDL) and results in total cholesterol levels greater than 90 percentiles. 
  • Phenotype V: Chylomicrons and very low-density lipoprotein (VLDL) are abnormal, and triglycerides are greater than 99 percentiles.

✅ Dyslipidemia differential diagnosis

A differential diagnosis is a list of possible medical conditions or diseases that can share the same symptoms as those experienced by a person. Below are some of the conditions that are included in the differential diagnosis of dyslipidemia: 

  • Biliary obstruction: It is the blockage or obstruction in the bile duct system resulting in leakage of bile from the intestines into the bloodstream. 
  • Nephrotic syndrome: It is the damage to kidneys that results in the excretion of high levels of protein in the urine. 
  • Pregnancy: Many studies provide evidence of the impact of dyslipidemia during pregnancy and the subsequent risk of atherogenesis for both mother and the fetus. 
  • Hypothyroidism: Dyslipidemia associated with hypothyroidism results in the intrahepatic accumulation of fats which leads to the development of non-alcoholic fatty liver disease.

✅ Considerations of general physician in developing accurate therapeutic drug regimen for dyslipidemia treatment

The physician takes into consideration the following points before initiating drug therapy for treating dyslipidemia:


  • The initial step is to decide which specific lipoprotein abnormalities need evaluation and whether they need drug treatment. 
  • The next step is to exclude secondary causes that may account for abnormal lipoprotein levels. These secondary causes may result from diet, disease conditions, or drug therapy.
  • Considering the presence of any genetic disorder. Enquiring patients whether his/her relatives have any medical history of cardiovascular disease, lipid disorder, or history of intake of lipid lowering agents. 
  • Lifestyle modifications are the initial treatment but in many patients drug therapy becomes essential. Physician chooses drugs on the basis of efficacy, safety, convenience, and cost.

✅ Dyslipidemia treatment goals

The treatment goals of dyslipidemia are:


  • To decrease low density lipoprotein (LDL) cholesterol levels 
  • To increase high density lipoprotein cholesterol (HDL) cholesterol levels
  • To reduce triglyceride levels
  • To prevent the risk of atherosclerotic cardiovascular disease including acute coronary syndrome, peripheral arterial disease, and stroke.
Request for appointment online for Dyslipidemia Treatment​ in Hyderabad, India

Book online appointment​

Dyslipidemia (High cholesterol or Hyperlipidemia) treatment in Hyderabad India

Dyslipidemia treatment

The criteria for the treatment of dyslipidemia primarily depend on the levels of low-density lipoproteins (LDL) with an aim to reduce the risk of cardiovascular disease in the future. 


Dietary interventions and lifestyle changes:

  • The treatment is focused on diet. Dietary modifications include a reduction in intake of saturated and trans-fat, cholesterol, and refined carbohydrates. While increasing the intake of unsaturated fats, fiber, plant sterols, and antioxidants.
  • Increased intake of fruits and vegetables compared to the percentage of ingested fat (lipids by 25 percent, carbohydrates by 55 percent, and proteins by 15 to 20 percent). 


Physical activity: 

  • Physical activity can improve the lipid profile, reduce blood pressure, improve insulin sensitivity, and promote weight loss. Cardiovascular risk can be prevented or reduced by improving endothelial function, reducing inflammation, and preventing thrombosis.
  • Moderate aerobic exercise for about 150 min or 75 min of vigorous intensity of aerobic exercise every week or a combination of both should be aimed by adults as recommended by the American Heart Association (AHA). 


Weight management and smoking cessation: 

  • Dyslipidemia patients who are obese should aim for a gradual weight loss up to 5 to 10 % of their initial body weight for 6 to 12 months which can be achieved by restricting calorie intake and with regular exercise. 
  • Smoking can affect lipid profile by enhancing the levels of low-density lipoproteins (LDL), and triglycerides, it also increases the risk of cardiovascular diseases by damaging endothelial lining causing inflammation and promoting oxidation of low-density lipoproteins (LDL) which in turn causes vasoconstriction due to aggregation of platelets. 
  • Smoking cessation can reverse these effects, improve the lipid profile, and reduce the risk of cardiovascular disorder. 


Pharmacological intervention: 

  • Pharmacological treatment should consider cardiovascular risk categorization, and the type of treatment depends on age, severity, and presence of familial cardiovascular risk factors. 
  • Statins are the first line treatment for dyslipidemia which acts by inhibiting 3 – hydroxy 3methylglutaryl – coenzyme A reductase. High-intensity statins are prescribed for patients aged less than 75 years and with clinically significant atherosclerotic cardiovascular disease (ASCVD). Moderate-intensity statins are prescribed for patients with atherosclerotic cardiovascular disease aged 75 or more. 
  • Patients aged between 40 to 75 with diabetic history and with low-density lipoprotein levels varying between 70 to 189 mg/dL are prescribed high-intensity statins. Patients aged between 40 to 75 years and with 10-year atherosclerotic cardiovascular disease greater than or equal to 7.5 percent should be on a moderate-intensity statin. 
  • With a moderate intensity, statin therapy should lower low-density lipoprotein levels by approximately 30 percent to less than 50 percent and greater than or equal to 50 percent with high-density statins for primary prevention. 
  • For a coronary artery disease patient, the goal is to achieve low-density lipoprotein levels of less than 70 mg/dL after being prescribed a high-intensity statin for about 6 weeks. Combination therapy is recommended in addition to high-intensity statin when low-density lipoprotein levels are significantly greater than 70 mg/dL. 
  • Statins as first-line treatment is recommended from 8 years of age, and are contraindicated in pregnancy. 
  • Bile acid scavengers act by binding to bile acids thereby reducing their absorption, increasing the hepatic synthesis, and decreasing the cholesterol content of hepatocytes. These are prescribed for patients aged above 6 years as monotherapy or with statins. These are rarely prescribed as they limit the absorption of fat-soluble vitamins and are less effective compared to statins. 
  • Cholesterol absorption inhibitors which act by inhibiting intestinal cholesterol absorption are usually prescribed to patients aged above 10 years, either as monotherapy or in combination with statins. They are also prescribed for children or adolescents with familial hypercholesterolemia, to patients with high-risk factors for premature cardiovascular disease, or to patients who do not reach their therapeutic goal with statin dose. 
  • Fibrates or fibric acid derivatives enhance lipolysis, reducing hepatic cholesterol synthesis thereby increasing clearance of very low-density lipoproteins (VLDL). Fibrates reduce triglyceride levels by 20 to 50 percent, low-density lipoproteins (LDL) by 15 percent, and increase high-density lipoproteins (HDL) by up to 20 percent.
Drug class Mechanism of action Effect on plasma lipids LDL – lowering.
Bile acid sequestrants Raises activity of low-density lipoprotein by impairing reabsorption of bile acids. Decreases levels of low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL), Minimal activity on high density lipoprotein (HDL) Depending upon the dose, reduces levels approximately 15 to 25 %
Pyridine carboxylic acids Acts by reducing hepatic secretion of very low-density lipoprotein (VLDL) Decreases low density lipoprotein (LDL), very low-density lipoproteins (VLDL). Increases high density lipoprotein (HDL) 5 to 20 %
Fibrates Acts by enhancing degradation of very low-density lipoprotein (VLDL) Decreases VLDL, small effect on LDL. Increases HDL levels 5 to 14%
MTP Inhibitors Acts by reducing hepatic secretion of very low-density lipoprotein Decreases VLDL and LDL 50 + %
Selective cholesterol absorption inhibitors Acts by increasing LDL receptor activity Decreases LDL and VLDL, shown minimal effect on HDL. 15 to 25%

✅Mixed dyslipidemia treatment

  • Patients with mixed or combined dyslipidemia require combination therapy to achieve lipid levels recommended by the US National Cholesterol Education Program Third Adult Treatment Panel (ATP III), as they are at high risk for developing cardiovascular events. 
  • Monotherapy with statin proved to be effective and by combination therapy, an additional benefit can be obtained by a greater reduction in levels of both low-density lipoprotein (LDL), and triglycerides and elevated levels of high-density lipoprotein (HDL).
  • For combination therapy, careful monitoring and evaluation of the risk-benefit ratio must be done. Clinical trials are conducted to obtain an optimal treatment plan for patients with combined dyslipidemia.

✅Treatment of dyslipidemia in pregnancy

  • In pregnancy, treatment recommendations for dyslipidemia are limited, as pregnant women are usually excluded from clinical trials. Omega 3 fatty acids, which act by decreasing maternal triglycerides (TG) are used as monotherapy and are considered safe. 
  • Pyridine carboxylic acids and fibrates decrease triglyceride levels and increase the levels of high-density lipoprotein (HDL) concentration. Neither pyridine carboxylic acids nor fibrates are recommended for treating dyslipidemia as they are not well studied in pregnancy.
  • Statins, which are first line treatments for dyslipidemia showed conflicting reports of teratogenicity and congenital malformation therefore, they are not recommended.

✅Diabetic dyslipidemia treatment

  • Patients with diabetic dyslipidemia are at a higher risk of developing atherosclerotic cardiovascular disease (ASCVD). Statin therapy is the first-line treatment in the majority of cases. 
  • Other lipid-lowering agents are recommended when individuals on statin therapy do not attain desired low-density lipoprotein (LDL) goals.

✅Prognosis of dyslipidemia

The prognosis depends on various factors such as type and severity of lipid disorder, presence of other risk factors of the cardiovascular system, adherence to lifestyle modifications, and occurrence of complications.


Some serious types of dyslipidemia require aggressive intervention than others. Genetic forms of dyslipidemia, such as familial hypercholesterolemia, cause high levels of low-density lipoprotein cholesterol and increase the risk of cardiovascular events.


Factors like diet, obesity, physical inactivity, tobacco smoking, and alcohol consumption can influence dyslipidemia. These factors can be modified by adapting to a healthy lifestyle. Other types of dyslipidemia are linked with some disease conditions like diabetes, hypothyroidism, and chronic kidney disease (CKD), this type of dyslipidemia can be improved by treating the underlying condition.

Dyslipidemia symptoms and causes | Dyslipidemia treatment in India | Dyslipidemia meaning

Dyslipidemia - Symptoms, Causes, Risk Factors, Diagnosis, and Treatment

By Pace Hospitals • October 3, 2024
Dyslipidemia is a condition characterized by abnormal cholesterol or lipid levels in the blood, increasing the risk of heart disease. Explore its symptoms, causes, risk factors, and how it’s diagnosed and treated with lifestyle changes and medication options.

Frequently Asked Questions (FAQs) on Dyslipidemia (High cholesterol or Hyperlipidemia)

  • What are the causes of dyslipidemia?

    Dyslipidemia has varied etiologies influenced by genetic, environmental, and lifestyle factors. It is categorized into primary and secondary dyslipidemia based on etiology. Primary dyslipidemia is caused by genetic mutations, it can be inherited as an autosomal dominant, autosomal recessive or X-linked.  Secondary dyslipidemia is caused by certain medications and some lifestyle factors that alter lipid levels in the blood.


  • What are the symptoms of dyslipidemia?

    Patients with severe dyslipidemia may develop few signs and symptoms linked to atherosclerosis. Some common symptoms of dyslipidemia include xanthomas (yellowish deposit of fats on the skin of eyelids and palms, arcus senilis (grey or white rings around the cornea of eyes), lipemia retinalis (milky appearance in the retinal vessels), lower limb ischemia, transient ischemic attacks and stroke. 


  • Who is most at risk for dyslipidemia?

    Individuals with a family history of high cholesterol, both children and adults, are more likely to develop dyslipidemia. Women are more likely to develop dyslipidemia compared to men after menopause. 

  • Which organs are affected by dyslipidemia?

    Dyslipidemia can cause cardiac hypertrophy, fibrosis, and arrhythmias by impairing the structure and function of the heart muscle. By altering lipid and glucose metabolism, dyslipidemia can affect the metabolism of other organs like the liver, pancreas, adipose tissue, and skeletal muscle. 

What is dyslipidemia?

Dyslipidemia refers to abnormal or impaired levels of lipids in the bloodstream. It is defined as increased levels of total cholesterol, low-density lipoprotein (LDL), and triglycerides (TG) with decreased levels of high-density lipoprotein (HDL) in the bloodstream. 

What is diabetic dyslipidemia?

Diabetic dyslipidemia is defined as a condition characterized by elevated levels of fasting triglycerides and decreased levels of high-density lipoprotein cholesterol (HDL). It is a determinant of atherogenesis and atherosclerotic progression in diabetic patients. 

Are dyslipidemia and hyperlipidemia the same thing?

No, dyslipidemia and hyperlipidemia are not the same thing. Dyslipidemia refers to abnormal levels of lipids in the blood whereas hyperlipidemia refers to increased levels of lipids such as cholesterol and triglycerides.

How is dyslipidemia classified?

Dyslipidemia is classified as primary dyslipidemia and secondary dyslipidemia. Primary dyslipidemias are heterogeneous groups of diseases that are inherited and are caused by genetic mutations, with mono or polygenic etiology. 


Secondary dyslipidemia is acquired and is caused by various external and lifestyle factors. Primary dyslipidemia affects lipid metabolism whereas secondary dyslipidemia alters lipid metabolism.

What is mixed dyslipidemia? 

Mixed dyslipidemia is defined as a hyperlipidemic pattern that is characterized by moderate to severe elevation in triglyceride (TG) and non-high-density lipoprotein cholesterol (non-HDL- C) with decreased high-density lipoprotein cholesterol (HDL – C) levels.

How does proteinuria cause dyslipidemia?

Proteinuria is associated with cholesterol and triglycerides, however low-density lipoprotein (LDL) levels are not elevated. The downregulation of lipoprotein lipase and LDL receptors is caused by chronic kidney disease (CKD). Delayed catabolism of triglycerides-rich lipoproteins leads to elevated levels of triglycerides. Reduced function of lecithin cholesterol acyltransferase (LCAT) and increased cholesteryl ester transferase protein leads to decreased high-density lipoprotein (HDL). 

Share by: